Boston Scientific saw a profit boom in the third quarter of the year, leading the company to increase its full-year forecast for 2025. The company is now projecting revenue growth of 20% for the ...

Boston Scientific’s BSX Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and ...

For most of the 20th century, cardiovascular disease (CVD) was perceived to be a predominantly male condition, leading to systematic under-recognition and under-treatment in women. Since its inception ...

Boston Scientific Corporation secured net sales of $5.203 billion during the first quarter of 2026, growing 11.6% overall.